Preclinical data suggest that modulation of the microbiota could become a novel strategy for improving the efficacy of immune-based therapies for cancer, in particular checkpoint blockade approaches targeting the CTLA-4 and PD-1 pathways [17, 18]. The gene discussed is CTLA4; the disease is cancer.